Viriom Inc. announced the successful conclusion of Phase I clinical trials for AV5124, an innovative inhibitor designed to target influenza virus replication. AV5124 has proven to be an exceptionally effective inhibitor of influenza virus RNA processing, exhibiting potency against various influenza types, including those resistant to neuraminidase inhibitors (Tamiflu®) or cap-dependent endonuclease inhibitors (Zoflusa®).
The recently finalized Phase I clinical studies have not only demonstrated the outstanding safety and tolerability of AV5124 but have also shown that blood drug levels achieved in the trials align with potent virus suppression for several days following a single oral exposure. Given its excellent safety profile and proven efficacy against influenza, AV5124 is now set to progress into Phase II-III efficacy studies, scheduled to commence during this year's influenza season.
Laboratory investigations supporting the development of AV5124 revealed its remarkable ability to significantly suppress Influenza A and Influenza B viruses, including drug-resistant variants. Moreover, AV5124 emerged as a potent inhibitor of highly pathogenic avian influenza viruses found in nature, indicating its potential application for seasonal or pandemic influenza treatment, as well as in pandemic preparedness. This significant advancement in influenza virus therapy underscores Viriom's unwavering commitment to advancing treatments that effectively address the evolving challenges posed by influenza and other infectious or malignant diseases.